G1 Therapeutics, a commercial-stage oncology biopharmaceutical company with a mission to develop and deliver next-generation therapies for cancer patients, will be hosting a webcast and conference call on May 1, 2024, to provide a financial and corporate update for the first quarter of 2024. The event will begin at 8:30 a.m. ET. To register for the event and receive the necessary dial-in information, interested individuals can follow the provided link on the company’s website. It is recommended to join the event 10 minutes prior to the start time.
G1 Therapeutics has developed COSELA® (trilaciclib), which is its first commercial product in their portfolio of therapies for cancer treatment. The company is also currently evaluating therapies in combination with cytotoxic therapies and/or immunotherapy for conditions with high unmet needs, such as triple-negative breast cancer and extensive stage small cell lung cancer. G1 Therapeutics aims to provide innovative therapeutic solutions for cancer patients by developing new treatments that improve outcomes and quality of life.
The company is headquartered in Research Triangle Park, N.C., where they are committed to advancing their mission through research and development efforts in oncology treatments. To learn more about G1 Therapeutics or their products, visit their website at http://www.g1therapeutics.com or follow them on social media platforms like X (formerly known as Twitter) @G1Therapeutics and LinkedIn for updates on their progress towards developing next-generation therapies for cancer patients.
For any further information or inquiries, individuals can contact G1 Therapeutics’ Communications Officer and Vice President of Investor Relations and Corporate Communications, Will Roberts, at (919) 907-1944 or via email at wroberts@g1therapeutics.com.
Trademarks owned by G1 Therapeutics include G1 Therapeutics®, COSELA®, and their respective logos.
To learn more about the upcoming webcast click here: [insert link]
Join us on May 1st at [insert time] ET as we provide an update on our financials & corporate progress! #G1Therapeutics #OncologyBiopharmaceuticalCompany #WebcastUpdate
